Helicobacter pylori eradication improves the prognosis of peptic ulcer disease (PUD), dyspepsia, and possibly gastric cancer. H pylori screening tests are accurate and eradication therapy is effective. H pylori population screening seems attractive. The aim of this study was to evaluate the long-term effect of H pylori population screening and eradication on dyspepsia prevalence and the incidence of PUD, and as secondary outcomes to assess the effect on health care consumption and quality of life.
and noninvasive, and H pylori can be eradicated by a well-tolerated, 1-week therapy. 6 From a public health perspective, it thus seems attractive and possibly cost effective to actively trace H pylori-infected individuals on a population scale.
HEP-FYN was designed to show the long-term effect of H pylori screening at the population level. 7 Additional register data on outcome and a large number of covariates were accessed for all randomized individuals, enabling us to evaluate the effect for all invited to screening and to assess the characteristics of nonresponders and thereby to evaluate selection bias.
Methods

Study Design and Study Population
HEP-FYN was a prospective intervention study initiated in 1998 to 1999. At baseline, 20,011 individuals ages 40 to 65 years living in the county of Funen, Denmark, were identified in the population register and allocated by a blind computerized randomization procedure to the H pylori screening and treatment group or the control group (no screening). Randomization was performed before invitation. Both groups received a questionnaire at inclusion, and after 1, 5, and 13 years.
The intervention was an invitation to screening for H pylori by an in-office blood test. Positive test results were confirmed by positive UBT. H pylori-positive individuals were offered triple eradication treatment (20 mg omeprazole, 500 mg clarithromycin, and 1 g amoxicillin [or 500 mg metronidazole] all twice daily for 1 week). In a random sample (n ¼ 200), UBT at least 4 weeks after eradication therapy showed an H pylori eradication rate of 95%. 7 Individuals who answered the 5-year questionnaire, who were alive and living in the county of Funen at the time of the 13-year follow-up evaluation, were sent a questionnaire. Second questionnaires were sent to nonresponders.
Outcomes
Our primary outcomes were the prevalence proportion of dyspepsia at the 13-year follow-up evaluation and the cumulative incidence of peptic ulcer disease (PUD). Secondary outcomes included the prevalence of reflux, dyspepsia-related health care use, and quality of life.
Questionnaire Data
The questionnaire included the Gastrointestinal Symptom Rating Scale (GSRS) 8 used to measure gastrointestinal symptoms within the past week. Dyspepsia was defined as a score of 2 or higher in the GSRS abdominal pain dimension, corresponding to mild to severe discomfort. 8 Gastroesophageal reflux disease (GERD) was defined as a score of 2 or higher in the reflux dimension in the GSRS.
The questionnaire covered smoking and average weekly alcohol consumption as well as dyspepsia-related sick leave days, general practitioner (GP) consultations, and use of ulcer drugs, antacids, aspirin, and NSAIDs, including over-the-counter use during the previous month.
Quality of life (QoL) was assessed by the Medical Outcome Study 36-item Short Form (SF-36) health survey. 9 
Register Data
All national registers can be linked using the unique personal identification number assigned to all Danish residents at birth or upon immigration. Register data were accessed for all randomized individuals via Statistics Denmark.
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Data were obtained for 2 periods. The first period comprised the 4 years before the index date and was used to evaluate responder vs nonresponder differences. The second period was from the index date to the 13-year follow-up date.
Data on all hospital contacts were obtained from the Danish National Patient Register. 11 Diagnoses were recorded according to the 8th and 10th revisions of the World Health Organization International Classification of Diseases (ICD). 12 The first recorded PUD diagnosis verified by upper endoscopy or surgery was categorized as index ulcers and was subcategorized as complicated or uncomplicated. Patients with a diagnosis of gastroesophageal cancer and esophagitis were identified. The number of upper endoscopies, hospital admissions, and outpatient visits with and without a related diagnosis of PUD were counted.
Comorbidity is an independent risk factor of gastrointestinal bleeding. 13 To correct for imbalances between groups, the Charlson Comorbidity Index (CCI) was calculated based on diagnoses for all hospital contacts in the Danish National Patient Register. 14 The CCI was modified to include ICD-8 and ICD-10 codes 12 (Supplementary Tables 1 and 2 ). A diagnosis of PUD was disregarded when computing the CCI for the analysis of the outcome incident PUD. We defined levels of comorbidity as low (0), medium (1), and high (!2).
Data were obtained from the Danish National Prescription Registry on the consumption of reimbursable ulcer drugs, H pylori eradication therapy, low-dose acetylsalicylic acid (ASA) ( 150 mg), high-dose ASA (!500 mg), and NSAIDs. High-dose ASA was reported together with NSAID use. Drug use was analyzed using the defined daily dose (DDD). 15 Information on the highest completed education level was obtained from the Populations Education Register. For simplification, the 16 International Classification of Education (1997) 16 levels were recoded into the following 4 categories: basic school education, secondary or short tertiary school education, long tertiary education, and unknown (Supplementary Table 3 ).
The Danish socioeconomic classification is based on labor-market attachment. 17 The Danish socioeconomic classification levels are employed, unemployed, retired, and unknown.
We obtained information from the Danish Civil Register on whether the person was living with a spouse or not.
Statistical Analyses
Assuming a 1-year dyspepsia prevalence of 25% in the population, inclusion of 7000 individuals per group would be sufficient to show a reduction in dyspepsia of 5%, accepting type 1 and type 2 errors of 5%. Conservatively, we assumed only individuals with peptic ulcer would have an effect of H pylori treatment on dyspepsia.
A significant reduction in the incidence of peptic ulcer and ulcer complications was seen in the screened group compared with the unscreened group at the 5-year follow-up evaluation. We expected this effect would be larger in an aging population with an expected increase in ASA and NSAID consumption.
The sample size was too small to assess effects on gastric cancer incidence in this low-prevalence region.
Completeness of recruitment at baseline. To evaluate whether there was an imbalance in baseline covariates for participating subjects owing to selective participation, we analyzed the association of baseline participation and randomization group, age, sex, previous PUD, comorbidity, the Danish socioeconomic classification, education group, and cohabitation in a logistic regression model including all randomized individuals.
Main outcomes. The point prevalence of dyspepsia at the 13-year follow-up evaluation was analyzed for all questionnaire responders at this follow-up evaluation (complete case analysis). Analysis of incident PUD was based on register data, therefore both intention-to-treat (ITT) and per-protocol (PP) analyses were possible. The association of these main outcomes and randomization group was explored using univariate and multivariate logistic regression. To account for imbalances between groups and outcomes, categoric variables for age, sex, ASA/NSAID, low-dose acetylsalicylic acid (LDA), CCI, and education were included in multivariate logistic regression models. Furthermore, the presence of dyspepsia at baseline or previous PUD was included as a covariate in the final model with the outcome of dyspepsia and PUD, respectively.
Secondary outcomes. Differences between randomization groups were compared using the chi-squared test, and the Mann-Whitney U test when appropriate.
From questionnaire data the differences in GP consultation rate, number of dyspepsia-related sick leave days, intergroup differences in QoL scores at baseline and at the 13-year follow-up evaluation, and changes in QoL from baseline to the end of the follow-up period were assessed.
Both PP and ITT analyses of secondary outcomes based on register data were performed.
Ethical Considerations
The Regional Medical Ethics Committee of the Region of Southern Denmark approved the protocol (project-ID: S-VF-20110054-97/262).
Data were handled according to the laws regulating private research registers and authorized by the Danish Data Protection Agency (project ID: 14/15606). 18 The study was registered at ClinicalTrials.gov (identifier: NCT02001727).
All authors had access to the study data and reviewed and approved the final manuscript.
Results
Study Population Flow
Of the 20,011 invited individuals at baseline, 12,530 (63%) were enrolled. A total of 5749 were screened for H pylori at baseline; 1007 (17.5%) were H pylori positive. Eradication therapy was refused or not completed in 24 of these H pylori-positive individuals. A total of 9641 individual were eligible and invited to the 13-year follow-up evaluation, and 8658 (90%) of these individuals participated, thus resulting in complete questionnaire data for 69% of the responders enrolled at baseline (Supplementary Figure 1) .
Completeness of Recruitment at Baseline
At baseline there were 4258 (43%) nonresponders in the screening group and 3223 (32%) in the control group. The mortality rate was significantly lower among baseline responders compared with nonresponders. During the 13-year follow-up period, 1238 (9.9%) baseline responders vs 1189 (15.9%) nonresponders died, resulting in a risk ratio (RR) of 0.62 (95% confidence interval [CI], 0.58-0.67).
At baseline, more responders than nonresponders were female, had previous PUD, were living with a spouse, had a higher education level, and were less likely to be retired (Table 1 ). Those individuals older than age 55 were more likely to participate than those in the youngest age group. There was no association between CCI score and baseline participation.
Characteristics of Questionnaire Responders at Baseline and at the 13-Year Follow-Up Evaluation
Comparison of baseline responders in the screening group and control group showed no difference in the distribution of age and sex (male, 49.5% vs female, 48.6%; mean age, 52.2 vs 52.2 y, respectively). Those individuals lost during the follow-up period were distributed equally in regard to sex and age between groups (male, 50.5% vs female, 50.5%; mean age, 52.6 vs 52.4 y, respectively).
Alcohol use was similar between groups and remained stable. The proportion of individuals who currently smoked decreased in both groups during the follow-up period.
The self-reported proportion of daily users of LDA and ASA/NSAIDs was higher at the 13-year follow-up evaluation than at baseline (LDA, 5.9%-17.4%; ASA/ NSAIDs, 3.2%-4.1%). The proportion of daily users of ulcer drugs was 3 times higher compared with baseline, whereas the use of over-the-counter antacids decreased. These changes were similar between groups.
Long-Term Effect on Dyspepsia Prevalence
At baseline, dyspepsia was significantly more prevalent in the screening group compared with the control group (24.8% vs 21.0%; odds ratio [OR], 1.26; 95% CI, 1.16À1.37) ( Table 2) , but not at the follow-up points. The prevalence of dyspepsia decreased slightly in both groups to 18.9% in the intervention group and 18.7% in the control group at the 13-year follow-up evaluation (Table 2) . Of the responders with dyspepsia at the 13-year follow-up evaluation, 48.5% also reported dyspepsia at baseline.
Complete case analysis of dyspepsia prevalence at the 13-year follow-up evaluation using logistic regression showed no effect of H pylori screening and eradication with an adjusted OR of 0.93 (95% CI, 0.82À1.04) (Supplementary Table 4 ).
Individuals with dyspepsia at baseline receiving H pylori eradication (n ¼ 172) did not have a significantly lower risk of dyspepsia at the 13-year follow-up evaluation compared with the H pylori negative individuals (n ¼ 764) with baseline dyspepsia (RR, 1.03; 95% CI, 0.89À1.19).
Long-Term Effect on Peptic Ulcer Disease Incidence
During the follow-up period, a total of 316 incident PUD cases occurred among the 12,530 responders enrolled at baseline (135 in the screened group vs 181 in the control group) ( Table 3 ). The PUD incidence rate was 1.9 vs 2.2 per 1000 persons per year, in the screening group and control group, respectively. The incidence rate ratio (IRR) was 0.87 (95% CI, 0.69-1.10).
Univariate and multivariate logistic regression analyses showed no effect of randomization on the incidence of PUD, either in the ITT (OR, 1.00; 95% CI, 0.80-1.13) or in the PP analysis (OR, 0.88; 95% CI, 0.70-1.11) (Supplementary Table 5 ).
During the 13-year follow-up period, 253 incident peptic ulcers occurred in nonresponders (n ¼ 7481)-an incidence rate of 2.8 per 1000 persons per year. The PUD incidence rate was significantly lower among baseline responders compared with nonresponders (IRR, 0.72; 95% CI, 0.61-0.86). The number of incident complicated peptic ulcers in the responders enrolled was 45 in the screened group vs 59 in the control group (Table 3) . The incidence of complicated peptic ulcers was significantly lower in individuals enrolled compared with nonresponders (IRR, 0.57; 95% CI, 0.43À0.75).
Gastroesophageal Reflux Disease
Analysis of baseline questionnaire data showed that GERD was significantly more prevalent in the screening group than in the control group (27.6% vs 23.7%, respectively; RR, 1.16; 95% CI, 1.10-1.24). There was no difference between groups in self-reported reflux symptoms (RR, 1.06; 95% CI, 0.98-1.15) ( Table 2) for the individuals followed up successfully for 13 years. However, there was a significantly higher number of hospital contacts with the diagnosis of esophagitis in the screened group when compared with the control group (PP analysis: RR, 1.24; 95% CI, 1.07-1.44) ( Table 3) .
Cancer
The total number of incident upper gastrointestinal cancers was 90 (0.5%) in all randomized individuals and 45 (0.5%) in the individuals enrolled, and the 
Health Resource Use
There was no difference in self-reported sick leave days or GP consultations for dyspepsia (Table 2) .
Register data for the 13-year follow-up evaluation are shown in Table 3 . There was no difference between groups in the proportion of individuals who had a PUDrelated hospital contact either in the ITT or in the PP analysis (RR, 0.94 and 0.87, respectively). The proportion of individuals who had at least 1 endoscopy during the follow-up period was similar between groups. The proportion of individuals who had more than 1 endoscopy was approximately 13% in both groups.
The number of proton pump inhibitor (PPI) users and the mean use of PPI (mean DDD per user) were significantly higher in the screened group for those enrolled compared with the control group of those enrolled (PP analysis). The number of H 2 -antagonist and ASA/NSAID users was significantly higher in the control group, but there was no difference in mean DDD per user between groups. These differences in use of prescription medication were not seen in the ITT analysis.
Quality of Life
At the 13-year follow-up evaluation, 7837 (91%) responders filled in the questionnaires assessing QoL, 87 questionnaires were excluded because of logical faults.
The SF-36 dimension and summary scores of physical health and mental health all decreased during the followup evaluation in both groups. No difference in the mean NOTE. Time of follow-up evaluation was estimated as the time from the index date to the index date þ 13 years or the index date until the death date. Low-dose ASA was 150 mg, and high-dose ASA was !500 mg. High-dose ASA is reported together with NSAID use. Bolded entries indicate significant results. PPI, proton pump inhibitors.
dimension or summary scores between groups was observed ( Table 2 and Figure 1 ).
Discussion
In this population-based, randomized, clinical trial with 13 years of follow-up evaluation, screening for H pylori did not reduce the prevalence of dyspepsia, the incidence of peptic ulcer disease significantly, and did not have a beneficial effect on health care consumption or quality of life.
The population sample was randomized before invitation and therefore the study shows the effect of screening on a population scale and can contribute to the evidence on systematic screening from a public health perspective. Two other randomized controlled studies with long-term follow-up evaluation invited a random population sample 19, 20 and only those found to be H pylori positive by screening were randomized (to eradication therapy or placebo) and followed up. These studies answer a related but entirely different question: whether an H pylori-positive screening test should be followed up by eradication therapy. They thus evaluated the effects of H pylori eradication exclusively in H pylori-positive individuals. By including the baseline population in our design, we also account for possible negative effects of screening in H pylori-negative subjects and in nonparticipants.
The high response rate was a strength. In addition, the prospective collection of data and the short recall period of the GSRS and SF-36 reduced recall bias.
Access to valid national registers on an individual level for all randomized individuals enabled us to characterize nonresponders. This reduced the influence of selection bias introduced by risk factors that can be measured in registries. Furthermore, it permitted event detection independent of participation, reducing nonresponse bias and bias from loss to follow-up evaluation and thus improved the internal validity.
From 2000 onward the diagnostic coding was used as the basis for payment of hospitals via the Diagnostic Related Group system. This provided a strong economic incentive for comprehensive coding, and the coding therefore can be assumed to be complete. 11 Inpatient and outpatient health care almost exclusively takes place under national health care services and the population coverage therefore also can be regarded as complete.
A limitation in using administrative data for event detection was that data were not collected for research purposes. This, however, also can be considered a strength because data were collected independently of the intervention and reflect current clinical practice. Variation in coding practices between doctors, departments or institutions, and over time poses a risk of misclassification bias. The inclusion of a nonvalid case would tend to dilute the ORs toward unity. The use of diagnoses from hospital contacts as the basis of comorbidity classification may introduce misclassification because this only measures illnesses that require hospital contact.
At the 5-year follow-up evaluation a modest reduction in the rate of dyspepsia, consultation rate, and sick leave days for dyspepsia, but no reduction in drug consumption, was observed. 21 A significant reduction in the incidence of peptic ulcer and ulcer complications was seen in the screened group compared with the unscreened group at the 5-year follow-up evaluation.
21 Figure 1 . SF-36 scores at the 13-year follow-up evaluation.
We expected this effect would be larger in an aging population with an expected increase in ASA and NSAID consumption. However, at the 13-year follow-up evaluation only a nonsignificant trend toward a lower incidence of peptic ulcer and ulcer complication was found in the intervention group compared with the control group. Several factors may explain this.
Baseline questionnaire data showed a possible selection effect; individuals with dyspepsia or reflux symptoms were more prevalent in the screening group than in controls. The analysis for selection showed that nonresponders were characterized by being male, retired, living alone, and having a low level of education.
Low socioeconomic status 22 and being a single male are known risk factors of PUD 1 and the H pylori prevalence is higher in this group. 22 Therefore, if more individuals had participated, the effect of H pylori screening might have been greater. Attrition as an explanation is supported further by the observed higher incidence of PUD, cancer, and death among nonresponders. The problem with attrition is known from other screening programs; the population group with assumed highest risk does not participate in screening programs. 23, 24 In Denmark, the prevalence of H pylori is low and this further dilutes the effect of eradication. Furthermore, during follow-up evaluation, 5% of the control group were H pylori tested and 3% received eradication therapy. This screening of the control group, probably as part of the H pylori test and treat strategy that has been implemented in Denmark during the past decade, dilutes the effect of the intervention further. However, the extent was small and did not compromise the study's ability to provide evidence of the effects of population screening.
At least 3 large studies have shown that neither H pylori presence nor H pylori eradication increases the prevalence of GERD. 19, 25, 26 These results are confirmed in this long-term follow-up evaluation in regard to selfreported symptoms of reflux. However, analysis of register data showed a significantly higher number of persons with a hospital contact with the diagnosis of esophagitis in the screened group compared with the unscreened group (P ¼ .004). This could reflect the imbalance at baseline in proportions reporting reflux symptoms (27.6% in the screened group vs 23.7% in the control group).
There was significantly higher use of PPIs in the screened group during follow-up evaluation and this could have enhanced a positive effect of screening on dyspepsia prevalence and PUD incidence. The higher use of PPIs in the screened group could be owing to a higher prevalence of GERD.
Screening in itself could have led to concern and anxiety in the screened group and led to over-reporting of symptoms. However, 48.5% of the responders with dyspepsia at the 13-year follow-up evaluation had reported dyspepsia at baseline.
The SF-36 dimension and summary scores all decreased during the follow-up period in both groups. In comparison with Danish Norm data, the same decrease has been observed with increasing age. 27 This study showed no long-term effect of H pylori screening on QoL. Our findings are in line with previous long-term studies. 19 
Conclusions
This randomized clinical trial with 13 years of followup evaluation was designed to provide evidence on the effect of H pylori screening at a population scale. It showed no significant long-term effect of population screening when compared with current clinical practice in a low-prevalence area. 
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